Sensyne Health appoints Dr Annalisa Jenkins as Acting Non-Executive Chair of the Board

Sensyne Health appoints Dr Annalisa Jenkins as Acting Non-Executive Chair of the Board

October 4, 2019

Oxford, UK: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, announces that Charles Swingland is recovering from a recent period of ill health which may take a number of weeks. In light of this, the Board has appointed Dr Annalisa Jenkins MBBS FRCP, Independent Non-Executive Director, as Acting Non-Executive Chair of the Board, effective immediately.  

Annalisa has a degree in Medicine from St. Bartholomew's Hospital, served as a medical officer in the British Navy and was a specialist registrar in Cardiovascular Medicine with the NHS. Her previous roles include SVP and Head of Global Medical at Bristol Myers Squibb, Head of Global R&D at Merck Serono and CEO of Dimension Therapeutics, a Nasdaq listed company that was acquired by Ultragenyx in 2017.

Annalisa is an experienced non-executive and currently chairs the boards of Cell Medica Limited, Vium Inc. and Cocoon Biotech Inc. She holds non-executive positions at the following publicly-listed companies: Ardelyx, Inc., Oncimmune Holdings plc, AVROBIO, Inc. and AgeX Therapeutics, Inc.  Annalisa is also a committee member of the Science Board of US FDA and Chair of the Court of the London School of Hygiene and Tropical Medicine.

-ENDS-

For more information please contact:

Sensyne Health (www.sensynehealth.com)
+44 (0) 330 058 1845

Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer

Peel Hunt LLP (Nominated Adviser and Broker)
+ 44 (0) 20 7418 8900

Dr Christopher Golden
James Steel
Oliver Jackson

Consilium Strategic Communications
+44 20 3709 5700

Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com

About Sensyne Health

Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology.

Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).